Time from emergency department admission until whole blood administration in whole blood cohort or receipt of red blood cells, plasma, and platelets in the component cohort.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Leeper CM, Yazer MH, Cladis FP, Saladino R, Triulzi DJ, Gaines BA. Use of Uncrossmatched Cold-Stored Whole Blood in Injured Children With Hemorrhagic Shock. JAMA Pediatr. 2018;172(5):491–492. doi:10.1001/jamapediatrics.2017.5238
Hemorrhagic shock is the most common cause of preventable death in pediatric civilian trauma.1 Balanced resuscitation with blood components has become the standard of care for initial hemostatic resuscitation in adults and children2-4 to mitigate the deleterious effects of trauma-induced coagulopathy.5 Whole blood (WB) contains plasma, red blood cells (RBCs), and platelets and requires less processing and dilution compared with reconstituting WB using components, making it an ideal resuscitative fluid. However, in non–group O recipients, there is a theoretical risk for hemolysis from anti-A and anti-B antibodies in group O WB units. Recently, the transfusion of WB in bleeding adult male trauma patients has been instituted in a large adult trauma center.6 Whole blood has never been transfused in a pediatric civilian trauma population; the novel use of transfusion of WB in injured children is herein described.
This study was conducted at Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center. Group O WB units were collected from male donors with low titers of both anti-A and anti-B antibodies (<50). Whole blood units were stored between 1°C and 6°C; those not used by storage day 14 were processed into an RBC unit for use elsewhere. One WB unit was stored in the emergency department (ED) of a pediatric level 1 hospital and additional units were stored in the hospital blood bank. Patients eligible for WB included injured children 3 years and older weighing 15 kg or more. These factors mitigate the risk for hemolysis; by age 3 years, children have full expression of A/B antigens that can adsorb anti-A and/or anti-B antibodies in the group O WB unit. Furthermore, children weighing 15 kg or more have a sufficient blood volume to dilute these antibodies. A maximum volume of 20 mL/kg of WB was chosen because it is nearly equivalent to 2 units of WB in adults, which had been proven safe in that population.6 A hemolysis panel including haptoglobin, total bilirubin, reticulocyte count, and lactate dehydrogenase was performed at the time of WB transfusion and on posttrauma days 1 and 2. Transfusion-related complications were recorded. The University of Pittsburgh institutional review board approved this study, which was conducted with a waiver of informed consent.
The median (interquartile range [IQR]) time elapsed from ED admission to receipt of at least 1 RBC, plasma, and platelet unit (time ending at the start of the third product administered) in a historical (2013-2016) pre-WB cohort of 50 traumatically injured children was compared with the median (IQR) time elapsed from ED admission to the start of the first WB transfusion among the WB recipients.
Between June 2016 and June 2017, 18 injured children received WB (Table).7,8 Eleven patients (61%) were male, 15 patients (83%) were of white race/ethnicity, and median (IQR) age was 11 (5-14) years. The median (IQR) injury severity score was 32 (25-42) and 8 patients (44%) died. Eight patients were blood group O, 10 patients were non–group O. Median (IQR) WB transfusion volume was 15 (9-23) mL/kg, roughly 1.5 (1-2) WB units. In 16 of these patients (88%), the first unit of WB was administered in the ED. The Wilcoxon rank sum test was used for comparison of nonparametric data; significance was set at P < .05. All P values are 2-tailed. There were no significant differences between group O and non–group O WB recipients at time of transfusion in biochemical hemolysis markers (1.25% vs 1.25%), in creatinine (0.009 mg/dL vs 0.007 mg/dL), and in potassium (4.05 mEq/L vs 3.70 mEq/L). There were no significant differences between the 2 groups on day 1 in biochemical hemolysis markers (1.40% vs 1.40%), in creatinine (0.005 mg/dL vs 0.005 mg/dL), and in potassium (3.80 mEq/L vs 3.80 mEq/L) (all P > .38). To convert reticulocyte count to proportion of red blood cells, multiply by 0.01; creatinine to μmol/L, multiply by 88.4; and potassium to μmol/L, multiply by 1.0. No transfusion reactions were reported. The median (IQR) time from ED admission to the start of the WB transfusion was 15 (14-77) minutes, compared with 303 (129-741) minutes (P < .001) for administration of at least 1 unit of RBCs, plasma, and platelets in the historical cohort (Figure).
To our knowledge, this is the first cohort of pediatric civilian trauma patients to receive WB during resuscitation. These preliminary data suggest that WB transfusion of up to 20 mL/kg is safe in children with severe injuries; there was no evidence of hemolysis in non–group O recipients, and no transfusion reactions were reported. Based on these data, the transfusion committee of Children’s Hospital of Pittsburgh of the University of Pittsburgh Medical Center approved an increase in maximum volume of WB transfusion to 30 mL/kg. Larger cohorts are necessary for further study to determine if WB administration will affect outcomes, including number of donor exposures, cost, total volume transfused, and mortality.
Corresponding Author: Christine M. Leeper, MD, MS, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, 7th Floor, Faculty Pavilion, One Children’s Hospital Dr, 4401 Penn Ave, Pittsburgh, PA 15224 (firstname.lastname@example.org).
Accepted for Publication: November 8, 2017.
Published Online: March 19, 2018. doi:10.1001/jamapediatrics.2017.5238
Author Contributions: Dr. Leeper had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: All authors.
Acquisition, analysis, or interpretation of data: Leeper, Yazer, Cladis, Saladino, Gaines.
Drafting of the manuscript: Leeper, Saladino.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Leeper.
Administrative, technical, or material support: Leeper, Yazer, Cladis, Triulzi.
Study supervision: Leeper, Yazer, Saladino, Gaines.
Conflict of Interest Disclosures: Dr Yazer received an honorarium from Terumo BCT, the manufacturer of the whole blood collection bag used in the study, for an invited lecture in 2015. No other disclosures were reported.
Create a personal account or sign in to: